|
Volumn 24, Issue 5, 2007, Pages 315-316
|
Do we need new clinical standards in management of acute myocardial infarction?
|
Author keywords
[No Author keywords available]
|
Indexed keywords
ACETYLSALICYLIC ACID;
ANGIOTENSIN RECEPTOR ANTAGONIST;
ATORVASTATIN;
BETA ADRENERGIC RECEPTOR BLOCKING AGENT;
CLOPIDOGREL;
DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;
FIBRINOLYTIC AGENT;
HEPARIN;
HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;
MORPHINE;
NITRATE;
OXYGEN;
SIMVASTATIN;
ACUTE HEART INFARCTION;
FIBRINOLYTIC THERAPY;
HEALTH CARE DELIVERY;
HEALTH CARE QUALITY;
HEART ARREST;
HEART MUSCLE REPERFUSION;
HIGH RISK PATIENT;
HUMAN;
MEDICAL AUDIT;
MORTALITY;
NOTE;
PERCUTANEOUS CORONARY INTERVENTION;
PRACTICE GUIDELINE;
PRIORITY JOURNAL;
QUALITY CONTROL;
SECONDARY PREVENTION;
SEPSIS;
ST SEGMENT ELEVATION;
STANDARD;
SURVIVAL RATE;
TREATMENT OUTCOME;
UNITED KINGDOM;
UNITED STATES;
VENTILATOR ASSOCIATED PNEUMONIA;
EMERGENCY MEDICINE;
EVIDENCE-BASED MEDICINE;
HUMANS;
MYOCARDIAL INFARCTION;
MYOCARDIAL REPERFUSION;
PRACTICE GUIDELINES;
QUALITY ASSURANCE, HEALTH CARE;
|
EID: 34247853214
PISSN: 14720205
EISSN: None
Source Type: Journal
DOI: 10.1136/emj.2007.047191 Document Type: Note |
Times cited : (1)
|
References (9)
|